MLAB News and Press, Mesa Laboratories Inc. From 02/09/23

Summary Cryoport has significantly underperformed the broader market over the past several months, largely due to poor earnings and cash flows. The company has excess cash on its books, but this doesn't make it a great prospect when you consider its continued profitability issues. A...

Mesa Laboratories press release ( NASDAQ: MLAB ): Q3 Non-GAAP EPS of $2.35 beats by $0.77 . Revenue of $54.29M (-0.7% Y/Y) misses by $2.76M . For further details see: Mesa Laboratories Non-GAAP EPS of $2.35 beats by $0.77, revenue of $54.29M misses by $2.76M

Summary Andvari Associates manages a concentrated investment strategy designed with the goal of outperforming the market. Since the firm's launch in 2013, our consolidated 'Andvari Core' strategy has meaningfully outperformed the market, net of all fees. In its 4th quarter letter, Andva...

LAKEWOOD, Colo., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2023 at approximately 8:00 A.M. Eastern time on Monday, February 6, 2023. About Mesa Laboratories, Inc. Mes...

Summary Breakout above 10-month-long downtrend. This has been observed in several names in our universe. Decent upsides versus consensus in the latest quarterly numbers, revenue is up 71% YoY as well. As such, the stock is well-positioned to prevent further downside, but there's not...

Lakewood, Colorado, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“we”, “Mesa” or the “Company”), a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthca...

LAKEWOOD, Colo., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or the “Company”) today announced that Shiraz Ladiwala has been appointed to serve as the Lead Independent Director of its Board of Directors (“Board”),...

Mesa Laboratories press release ( NASDAQ: MLAB ): Q3 GAAP EPS of $0.24 beats by $0.55 . Revenue of $58.75M (+71.9% Y/Y) beats by $5.27M . For further details see: Mesa Laboratories GAAP EPS of $0.24 beats by $0.55, revenue of $58.75M beats by $5.27M

Summary Mesa Laboratories has been compressed heavily on the chart this year to date. The company's bottom-line fundamentals have been weakening on a sequential basis. This isn't backed by the return on the company's invested capital to overcome this and the WACC hurdle. H...

The following slide deck was published by Mesa Laboratories, Inc. in conjunction with their 2023 Q1 earnings call. For further details see: Mesa Laboratories, Inc. 2023 Q1 - Results - Earnings Call Presentation